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ABSTRACT 
The  common  presentations  of  lymphoma  are  widespread  lymphadenopathy  or  development  of  constitutional 
symptoms. This paper presents a case of a patient who presented with a solitary mass detected on chest X ray and 
underwent FDG PET for further evaluation of this mass. FDG PET is a commonly utilised technique to assess solitary 
nodules as it not only allows characterisation of the lesion but can also detect nodal and extra thoracic disease with 
greater accuracy than the standard CT. In this case, FDG PET demonstrated abnormal activity in the lung nodule and at 
the gastro oesophageal junction. Biopsies confirmed Non Hodgkin’s Lymphoma at both sites. The value of FDG PET in 
this case was the determination of previous unsuspected disease in an unusual presentation of lymphoma and as a useful 
tool for monitoring the therapeutic effect post chemotherapy. © 2007 Biomedical Imaging and Intervention Journal. All 
rights reserved. 
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LEARNING POINTS 
A 71 year old lady had an incidental finding of an 
opacity  in  her  left  lower  lobe  on  a  chest  radiograph. 
Thoracic CT confirmed the presence of a 1.0 cm solitary 
pulmonary  nodule  but  did  not  identify  any 
lymphadenopathy  or  evidence  of  distant  metastatic 
disease.  
The patient was referred for an F
18 FDG PET study 
(Figure 1) for investigation of the pulmonary nodule [1]. 
The PET study confirmed a small retrocardiac focus of 
increased FDG uptake within the left lower lobe nodule 
(thin  arrow)  suggestive  of  a  malignant  process.  In 
addition,  the  study  demonstrated  abnormal  increased 
activity at the gastro oesophageal junction (thick arrow). 
It  was  proposed  that  metastasis  at  this  site  from  a 
primary lung malignancy would be unusual and that two 
malignancies  (i.e.  lung  and  gastric)  were  possible  [2]. 
Lung  metastasis  from  a  gastric  neoplasm  was  also 
possible,  however,  isolated  pulmonary  metastasis  from 
gastric  cancer  is  rare.  Thus,  further  investigation  was 
recommended. 
The  patient  underwent  upper  gastrointestinal 
endoscopy. Biopsy of the gastric wall during endoscopy 
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revealed non Hodgkin’s lymphoma (NHL). The patient 
proceeded to thoracotomy for investigation of her lung 
lesion to definitively ascertain the nature of this lesion. 
Pathology  again  confirmed  lung  NHL.  Therefore,  the 
patient  was  treated  with  systemic  chemotherapy  for 
lymphoma. 
A follow up post therapy FDG PET study (Figure 2, 
right)  showed  a  complete  metabolic  response  to 
treatment  both  in  the  stomach  and  the  left  lung  when 
compared to the initial study (Figure 2, left). 
DISCUSSION 
Non Hodgkin’s lymphoma is a known but relatively 
rare  cause  of  solitary  pulmonary  nodules  [3]. 
Gastrointestinal lymphoma can be FDG avid but can be 
difficult to differentiate from normal stomach activity [4]. 
Likewise,  it  can  be  difficult  to  appreciate  with 
anatomical imaging  methods such as CT. In this case, 
however,  the  gastric  uptake  of  FDG  was  focal  and 
somewhat more intense than is usually seen at the gastro 
oesophageal  junction.  This  led  to  the  suspicion  of  a 
pathological process at this site, which was subsequently 
confirmed at biopsy. Lymphoma is usually characterised 
by  nodal  involvement  on  both  CT  and  FDG PET. 
Extranodal disease is less common. The unusualness of 
this  presentation  necessitated  tissue  confirmation  both 
from the stomach and the lung nodule. 
FDG PET  is  used  throughout  the  world  in  the 
assessment  of  solitary  pulmonary  nodule.  It  has  been 
shown  to  have  high  sensitivity  (>95%)  and  high 
specificity (>75%) in determining whether the nodule is 
benign or malignant based on high uptake in the lesion 
[5]. In this case, FDG PET confirmed a likely malignant 
process with prominent activity seen in the small lung 
nodule.  
FDG PET in this case also showed a total metabolic 
response  to  treatment  following  appropriate 
chemotherapy.  In  the  authors'  institution,  post therapy 
assessment  in  NHL  is  one  of  the  most  common 
indications  for  FDG PET.  The  findings  may  be  of 
prognostic significance as total metabolic response has 
been  associated  with  improved  long  term  outlook  in 
NHL  [6].  FDG PET  has  also  been  shown  to  be  more 
accurate  in  assessing  response  to  therapy  in  NHL 
compared with CT [7]. The whole body nature of PET 
imaging  coupled  with  the  sensitivity  related  to  its 
assessment  of  metabolic  function  rather  than  anatomic 
detail  likely  contribute  to  its  enhanced  accuracy 
compared to CT.  
This  case  thus  illustrates  the  usefulness  of  FDG 
PETas teaching points: 
●  in  the  assessment  of  the  solitary  pulmonary 
nodule 
●  in the detection of previously occult disease and  
●  as  a  sensitive  modality  for  monitoring 
therapeutic efficacy in lymphoma. 
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Figure 1  The PET study (Philips Allegro system) reveals a small retrocardiac focus of increased FDG uptake 
within the left lower lobe nodule (thin arrow) suggestive of a malignant process. In addition, the study 
demonstrates abnormal increased activity at the gastro oesophageal junction (thick arrow). 
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Figure 2  A follow up FDG PET study post therapy (left) shows a complete metabolic response to treatment both 
in the stomach and the left lung when compared to the initial study (right). 
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